{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=8", "query": { "intervention": "Advanced therapy", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 6311, "total_pages": 632, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T21:05:00.434Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02322281", "title": "TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib", "type": "DRUG" }, { "name": "Pemetrexed or gemcitabine or paclitaxel or docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2015-02", "completion_date": "2018-03-29", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 31, "location_summary": "Bakersfield, California • Duarte, California • Fullerton, California + 27 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02322281" }, { "nct_id": "NCT00896181", "title": "Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Lymphoepithelioma of the Nasopharynx", "Stage II Squamous Cell Carcinoma of the Nasopharynx", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 26, "start_date": "2008-12-10", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896181" }, { "nct_id": "NCT05746039", "title": "Feasibility of Semaglutide in Advanced Lung Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Obesity", "Interstitial Lung Disease", "Chronic Obstructive Pulmonary Disease", "Sarcoidosis, Pulmonary", "Pulmonary Hypertension" ], "interventions": [ { "name": "Semaglutide Pen Injector", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 8, "start_date": "2024-01-29", "completion_date": "2027-12-28", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05746039" }, { "nct_id": "NCT01239160", "title": "Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphedema", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphedema" ], "interventions": [ { "name": "Flexitouch System", "type": "DEVICE" }, { "name": "Hydroven FPR", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Tactile Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2010-11-02", "completion_date": "2012-06-27", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Springfield, Illinois + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239160" }, { "nct_id": "NCT04421820", "title": "BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Gastric Cancers", "Cholangiocarcinoma" ], "interventions": [ { "name": "BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)", "type": "DRUG" }, { "name": "BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bold Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2020-08-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 2, "location_summary": "Santa Monica, California • Tampa, Florida", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421820" }, { "nct_id": "NCT03875313", "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-05-20", "completion_date": "2020-07-29", "has_results": true, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875313" }, { "nct_id": "NCT01802320", "title": "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Mucinous Adenocarcinoma", "Colon Signet Ring Cell Adenocarcinoma", "Rectal Mucinous Adenocarcinoma", "Rectal Signet Ring Cell Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-03", "completion_date": "2015-08-05", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802320" }, { "nct_id": "NCT00900679", "title": "Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Transitional Care Planning" ], "interventions": [ { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 110, "start_date": "2008-07", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2010-08-11", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900679" }, { "nct_id": "NCT00126503", "title": "Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2005-05", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2015-01-15", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126503" }, { "nct_id": "NCT01415986", "title": "Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Temoporfin", "type": "DRUG" }, { "name": "Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 1, "start_date": "2010-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2012-12-03", "last_synced_at": "2026-11-11T21:05:00.434Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415986" } ] }